Louisiana House Bill HB375

Louisiana 2015 Regular Session

• Introduced: 4/2/15
• Refer: 4/2/15
• Refer: 4/13/15

Caption

Exemption for certain ophthalmic drugs administered in a physician's office (OR DECREASE LF RV See Note)

Impact

In terms of state laws, HB 375 adds a new exemption under Louisiana's tax code, specifically R.S. 47:305.72 and 337.9(D)(34). This addition will allow for broader tax exemptions on specific medical services, contributing to a more favorable tax environment for those needing ocular treatments. Although intended to reduce costs for patients, it may also impact local revenue streams depending on how these exemptions are applied across different jurisdictions in Louisiana.

Summary

House Bill 375 seeks to implement a state and local sales and use tax exemption for the procurement and administration of certain ophthalmic injectable drugs. This exemption applies specifically to drugs used solely for a patient’s medical treatment and administered exclusively in a physician's office, thereby excluding any institutions where patients stay for extended periods. This legislation aims to alleviate financial burdens associated with these medical treatments, potentially making ophthalmic care more accessible to patients in Louisiana.

Sentiment

The sentiment around HB 375 appears to be cautiously optimistic among supporters, who argue that such an exemption is necessary to improve access to healthcare for patients needing eye care without the added financial strain. However, there may be concerns from local authorities about the long-term implications of reduced tax revenue and how that could affect funding for community services.

Contention

A notable point of contention is whether the tax exemption could lead to unintended consequences in terms of budgeting for local governments. While the bill aims to provide immediate financial relief to patients, local governments may argue that this could jeopardize funding for necessary local programs. There is also a discussion on defining the criteria for what qualifies as ophthalmic drugs under the exclusion, which could lead to further debate among legislators and stakeholders in the healthcare sector.